Quick Answer
GT Biopharma, Inc. reported Earnings Per Share Diluted of $6.68 (loss) per share for the year ending 2025.
- GT Biopharma, Inc. showed an increase of +3.7% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from GT Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2016 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 7 years of available data (2016 to 2025), GT Biopharma, Inc.'s Earnings Per Share Diluted has declined by 105.6%.
- Historical annual values: Fiscal year 2025: $6.68 (loss) per share | Fiscal year 2024: $6.94 (loss) per share | Fiscal year 2023: $5.64 (loss) per share | Fiscal year 2022: $19.66 (loss) per share | Fiscal year 2018: $5.16 (loss) per share | Fiscal year 2017: $8.60 (loss) per share | Fiscal year 2016: $119.91 per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: